RxDoctor Payments Data

Marco Davila, MD

Medical Oncology · Buffalo, NYNPI 1326204322

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $322,743 of the $437,189 with a category attached, or 73.8%. 11 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 50.5% of the total. 2025 is the largest year on record at $194,162, 7.5 times the $25,918 reported in 2019. Among medical oncology clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$437,189in general payments, 2019–2025

Across 324 payments — averaging $1349.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$221K
  • Gilead$175K
  • Novartis$11K
  • Bristol Myers Squibb$9K
  • Incyte Corporation$7K
  • Legend Biotech USA Inc.$6K
  • plus $8K from 5 others
$362,659in research payments, 2019–2025

Across 3 payments — averaging $120,886 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$363K

What the payments were for

  • Consulting fees$54,33512%
  • Speaking & faculty fees$322,74374%
  • Travel & lodging$49,00411%
  • Food & beverage$11,1063%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
E.r. Squibb & Sons, L.L.C.138$220,904
Gilead(2 entities)112$174,779
Novartis38$11,486
Bristol Myers Squibb12$9,158
Incyte Corporation9$7,056
Legend Biotech USA Inc.9$6,257
GSK1$5,937
Johnson & Johnson2$925
ADIR1$550
ADC Therapeutics America, Inc.1$100
Sobi, Inc1$37

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$437,189 in reported general payments places this provider in the 95th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024
$7,957
Medicare patients
29
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Buffalo

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →